Pectolinarigenin ameliorated airway inflammation and airway remodeling to exhibit antitussive effect
10.4196/kjpp.2024.28.3.229
- Author:
Quan HE
1
;
Weihua LIU
;
Xiaomei MA
;
Hongxiu LI
;
Weiqi FENG
;
Xuzhi LU
;
Ying LI
;
Zi CHEN
Author Information
1. Department of Respiratory and Critical Care Medicine, Zhenjiang Hospital of Integrated Traditional Chinese and Western Medicine, Zhenjiang, Jiangsu 212000, China
- Publication Type:Original Article
- From:The Korean Journal of Physiology and Pharmacology
2024;28(3):229-237
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Cough is a common symptom of several respiratory diseases. However, frequent coughing from acute to chronic often causes great pain to patients. It may turn into cough variant asthma, which seriously affects people's quality of life. For cough treatment, it is dominated by over-the-counter antitussive drugs, such as asmeton, but most currently available antitussive drugs have serious side effects. Thus, there is a great need for the development of new drugs with potent cough suppressant. BALB/c mice were used to construct mice model with cough to investigate the pharmacological effects of pectolinarigenin (PEC). Hematoxylin-eosin and Masson staining were used to assess lung injury and airway remodeling, and ELISA was used to assess the level of inflammatory factor release. In addition, inflammatory cell counts were measured to assess airway inflammation. Airway hyperresponsiveness assay was used to assess respiratory resistance in mice. Finally, we used Western blotting to explore the potential mechanisms of PEC. We found that PEC could alleviate lung tissue injury and reduce the release of inflammatory factors, inhibit of cough frequency and airway wall collagen deposition in mice model with cough. Meanwhile, PEC inhibited the Ras/ERK/c-Fos pathway to exhibit antitussive effect. Therefore, PEC may be a potential drug for cough suppression.
